Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian stock markets open weak
Mon, 29 Jul 09:30 am

The major Asian stock markets have opened in the red with stock markets in Japan (down 2.5%) and China (down 1.6%) leading the losses. The Indian stock markets indices have also opened the day on a weak note. The sectoral indices have opened mixed with stocks in the FMCG and banking sector leading the losses. However, stocks in the oil and gas and consumer durables were leading the gains.

The Sensex today is down by around 20 points (0.1%), while the NSE-Nifty is down by around 13 points (0.2%). Mid cap stocks have opened in the red with the BSE Mid Cap index down by around 0.4%. However, the small cap stocks have opened in the green with the BSE Small Cap index up by around 0.1%. The rupee is trading at Rs 59.12 to the US dollar.

PSU Banking stocks have opened mainly in the red with Syndicate Bank and Dena Bank leading the losses. Corporation Bank has announced results for the first quarter of the financial year 2013-14 (1QFY14). The bank has reported a net profit growth of 2.1% on a year on year (YoY) basis. The net interest income (NII) during the period was up by 19.34 % YoY while non-interest income grew by 77.41 % YoY. The gross non-performing assets (NPA) at the end of the quarter stood at 2.37 % while the net NPA came in at at 1.65 %. The NPA provision coverage ratio stood at 56.79 % with reference to gross NPA. The capital adequacy ratio stood at 12.1% at the end of June 2013.

Indian Pharma stocks have opened the day on a mixed note with Natco Pharma and Torrent Pharma leading the gains. However, Sun Pharma and Wockhardt Ltd were facing losses. As per a leading financial daily, the pharmaceutical companies that are operating in US are likely to be subjected to tighter drug approval norms. The US Food & Drug Administration (USFDA) has mandated companies to give data from January 2014 including on safety, efficacy and stability - for three batches of products, instead of one at present, while seeking drug approvals in that country. This may lead to a significant increase in the time and development cost of generic products from next year for companies like Sun Pharmaceuticals Ltd, Lupin, Dr Reddy's Laboratories, Ranbaxy Ltd etc. The move is likely to increase the cost - by up to three times in cases where ingredients used are expensive.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian stock markets open weak". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.